Nephrotoxicity - What do we know and what don't we know?

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 2, 2011, Pages 128-134

  Skinner, Roderick ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

chemotherapy; child; drug toxicity; kidney; late sequelae

Indexed keywords

ACROLEIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CHLOROACETALDEHYDE; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; IFOSFAMIDE; IMATINIB; MELPHALAN; MESNA; METHOTREXATE; NITROSOUREA; PANITUMUMAB; PLATINUM COMPLEX;

ACUTE KIDNEY FAILURE; ACUTE TOXICITY; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC KIDNEY FAILURE; CHRONIC TOXICITY; CLINICAL FEATURE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; PATHOGENESIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHILD; HUMANS; KIDNEY; KIDNEY DISEASES; NEOPLASMS;

EID: 79952192991     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181f8cac0     Document Type: Article

References (92)

1. Brandt LJ, Broadbent V. Nephrotoxicity following carboplatin use in children: Is routine monitoring of renal function necessary? Med Pediatr Oncol. 1993;21:31-35. (Pubitemid 23018173)
2. Hayes FA, Green AA, Casper J, et al. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: Response and toxicity. Cancer. 1981;48:1715-1718. (Pubitemid 11022872)
3. Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: A review of published findings. J Clin Oncol. 2009;27:2339-2355.
4. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. The Renal Insufficiency and Anticancer Medications (IRMA) Study. Cancer. 2007;110: 1376-1384. (Pubitemid 47435612)
5. Douville P, Martel AR, Talbot J, et al. Impact of age on glomerular filtration estimates. Nephrol Dial Transplant. 2009;24:97-103.
6. Lewis MA, Shaw J, Sinha M, et al. Demography of the UK paediatric renal replacement therapy population. In: Ansell D, Feest T, Williams A, et al, eds. UK Renal Registry Report 2008. Bristol: UK Renal Registry; 2008:257-267.
7. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. New Eng J Med. 2006;355:1572-1582. (Pubitemid 44547808)
8. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 2003;41:190-197. (Pubitemid 36910127)
9. Skinner R, Pearson ADJ, Coulthard MG, et al. Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol. 1991;28:81-92.
10. Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987;71:131-135. (Pubitemid 17030141)
11. Piepsz A, Colarinha P, Gordon I, et al. 14 July 2010. Guidelines for glomerular filtration rate determination in children. EANM Guidelines 2000. https://www.eanm.org/scientific-info/guidelines/gl-paed-gfrd.pdf [Accessed July 14, 2010].
12. Skinner R, Cotterill S, Stevens MCG, et al. Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG late effects group study. Br J Cancer. 2000;82:1636-1645. (Pubitemid 30229572)
13. De Schepper J, Hachimi-Idrissi S, Verboven M, et al. Renal function abnormalities after ifosfamide treatment in children. Acta Paediatr. 1993;82:373-376. (Pubitemid 23142853)
14. Skinner R, Pearson ADJ, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet. 1996;348:578-580. (Pubitemid 26283889)
15. Stohr W, Paulides M, Bielack S, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer. 2007;48: 447-452. (Pubitemid 46340112)
16. Heney D, Wheeldon J, Rushworth P, et al. Progressive renal toxicity due to ifosfamide. Arch Dis Child. 1991;66:966-970.
17. Willemse PHB, de Jong PE, Elema JD, et al. Severe renal failure following high-dose ifosfamide and mesna. Cancer Chemother Pharmacol. 1989;23:329-330. (Pubitemid 19087695)
18. Prasad VK, Lewis IJ, Aparicio SR, et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol. 1996;27:149-155. (Pubitemid 26282094)
19. Al Sheyyab M, Worthington D, Beetham R, et al. The assessment of subclinical ifosfamide-induced renal tubular toxicity using urinary excretion of retinol-binding protein. Pediatr Hematol Oncol. 1993;10:119-128. (Pubitemid 23151986)
20. Goren MP, Wright RK, Horowitz ME, et al. Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein. Am J Clin Pathol. 1986;86:780-783. (Pubitemid 17194985)
21. Skinner R, Sharkey IM, Pearson ADJ, et al. Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol. 1993;11:173-190.
22. Ashraf MS, Brady J, Breatnach F, et al. Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Paediatr. 1994;153: 90-94. (Pubitemid 24052700)
23. Friedlaender MM, Haviv YS, Rosenmann E, et al. End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy. Am J Nephrol. 1998;18:131-133. (Pubitemid 28161819)
24. Loebstein R. Risk factors for long-term outcome of ifosfamide- induced nephrotoxicity in children. J Clin Pharmacol. 1999;39:454-461. (Pubitemid 29356465)
25. Rossi R, Godde A, Kleinebrand A, et al. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail. 1995;17:551-557.
26. Goren MP, Pratt CB, Viar MJ. Tubular nephrotoxicity during long-term ifosfamide and mesna therapy. Cancer Chemother Pharmacol. 1989;25:70-72. (Pubitemid 20000802)
27. MacLean FR, Skinner R, Hall AG, et al. Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: A preliminary observation. Cancer Chemother Pharmacol. 1998;41:413-416. (Pubitemid 28095758)
28. Burk CD, Restaino I, Kaplan BS, et al. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr. 1990;117:331-335. (Pubitemid 20238556)
29. Stohr W, Patzer L, Paulides M, et al. Growth impairment after ifosfamide-induced nephrotoxicity in children. Pediatr Blood Cancer. 2007;48:571-576. (Pubitemid 46496355)
30. Caron HN, Abeling N, van Gennip A, et al. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol. 1992;20:42-47.
31. Van Gool S, Brock P, Wijndaele G, et al. Reversible hypophosphatemic rickets following ifosfamide treatment. Med Pediatr Oncol. 1992;20:254-257.
32. Ashraf MS, Skinner R, English MW, et al. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol. 1997;28:62-64. (Pubitemid 27023779)
33. Skinner R, Parry A, Price L, et al. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer. 2010;54: 983-989.
34. Oberlin O, Fawaz O, Rey A, et al. Long-term evaluation of ifosfamide-related nephrotoxicity in children. J Clin Oncol. 2009;27:5350-5355.
35. Raney B, Ensign LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for patients with gross residual disease. Am J Pediatr Hematol Oncol. 1994;16:286-295. (Pubitemid 24364716)
36. Shore R, Greenberg M, Geary D, et al. Iphosphamide-induced nephrotoxicity in children. Pediatr Nephrol. 1992;6:162-165.
37. Rossi R, Godde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamideinduced nephrotoxicity: Analysis of 120 patients. J Clin Oncol. 1994;12:159-165.
38. Boddy AV, English MW, Pearson ADJ, et al. Ifosfamide nephrotoxicity: Limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer. 1996;32A:1179-1184. (Pubitemid 26231800)
39. Rossi R, Schafers P, Pleyer J, et al. The influence of short versus continuous ifosfamide infusion on the development of renal tubular impairment. Int J Pediatr Hematol Oncol. 1997;4:393-399. (Pubitemid 27501003)
40. Pratt CB, Meyer WH, Jenkins JJ, et al. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol. 1991;9:1495-1499.
41. Elias AD, Ayash LJ, Eder JP, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991;9:320-327.
42. Hanly L, Chen N, Rieder M, et al. Ifosfamide nephrotoxicity in children: A mechanistic base for pharmacological prevention. Expert Opin Drug Saf. 2009;8:155-168.
43. Skinner R, Parry A, Price L, et al. Persistent nephrotoxicity during ten year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. Eur J Cancer. 2009;45:3213-3219.
44. Kamalaker P, Freeman AI, Higby DJ, et al. Clinical response and toxicity with cis-dichlorodiammine-platinum (II) in children. Cancer Treat Rep. 1977;61:835-839. (Pubitemid 8167609)
45. Stohr W, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer. 2007;48: 140-147. (Pubitemid 44958269)
46. Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. J Pediatr. 1985;106:659-663. (Pubitemid 15080566)
47. Brock PR, Koliouskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr. 1991;118:531-534.
48. Hartmann O, Pinkerton CR, Philip T, et al. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988;6:44-50. (Pubitemid 18039989)
49. Pratt CB, Hayes A, Green AA, et al. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: A phase II study. Cancer Treat Rep. 1981;65:1021-1026. (Pubitemid 12237731)
50. Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med. 1978;65:307-314. (Pubitemid 9003377)
51. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol. 1988;21:163-167. (Pubitemid 18087031)
52. Lam M, Adelstein DJ. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis. 1986;8:164-169. (Pubitemid 17217090)
53. Bianchetti MG, Kanaka C, Ridolfi-Luthy A, et al. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. Pediatr Nephrol. 1990;4: 219-222. (Pubitemid 20186993)
54. Daugaard G, Abildgaard U, Holsten-Rathlou NH, et al. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther. 1988;44:164-172.
55. Bellin SL, Selim M. Cisplatin-induced hypomagnesemia with seizures: A case report and review of the literature. Gynecol Oncol. 1988;30:104-113.
56. Rude RK, Oldham SB, Singer FR. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol. 1976;5: 209-224.
57. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1989;25:1-9.
58. Kurtzberg J, Dennis VW, Kinney TR. Cisplatinuminduced renal salt wasting. Med Pediatr Oncol. 1984;12: 150-154.
59. Wong NLM, Walker VR, Wong EFC, et al. Mechanism of polyuria after cisplatin therapy. Nephron. 1993;65:623-627. (Pubitemid 23341518)
60. Verplanke AJW, Herber RFM, de Wit R, et al. Comparison of renal function parameters in the assessment of cis-platin induced nephrotoxicity. Nephron. 1994;66:267-272. (Pubitemid 24054814)
61. Ettinger LJ, Douglass HO, Higby DJ, et al. Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma. Cancer. 1981;47:248-254. (Pubitemid 11179318)
62. Harrell RM, Sibley R, Vogelzang NJ. Renal vascular lesions after chemotherapy with vinblastine, bleomycin and cisplatin. Am J Med. 1982;23:429-433. (Pubitemid 12031797)
63. Canpolat C, Pearson P, Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer. 1994;74:3059-3062. (Pubitemid 24361095)
64. Skinner R, Pearson ADJ, English MW, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer. 1998;81:336-341.
65. Preiss R, Brovtsyn VK, Perevodchikova NI, et al. Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin. Eur J Clin Pharmacol. 1988;34:139-144. (Pubitemid 18091928)
66. Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5:304-309. (Pubitemid 17021616)
67. Children's Oncology Group. 2004. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. [Accessed July 14, 2010].
68. Skinner R, Wallace WHB, Levitt GA. 2005 14 July 2010. Therapy based long term follow up: Practice Statement. United Kingdom Children's Cancer Study Group (Late Effects Group) [Accessed July 14, 2010].
69. Broadhead CL, Walker D, Skinner R, et al. Differential cytotoxicity of ifosfamide and its metabolites in renal epithelial cell cultures. Toxicol in vitro. 1998;12:209-217. (Pubitemid 28331384)
70. Mohrmann M, Ansorge S, Schmich U, et al. Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatr Nephrol. 1994;8:157-163. (Pubitemid 24092249)
71. Nissim I, Weinberg JM. Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats. Kidney Int. 1996;49: 684-695. (Pubitemid 26093077)
72. Rossi R. Nephrotoxicity of ifosfamide-moving towards understanding the molecular mechanisms. Nephrol Dial Transplant. 1997;12:1091-1092. (Pubitemid 27230536)
73. Tasso MJ, Boddy AV, Price L, et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol. 1992;30:207-211.
74. Mohrmann M, Pauli A, Walkenhorst H, et al. Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture. Renal Physiol Biochem. 1993;16:285-298. (Pubitemid 23331468)
75. Zamlauski-Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol. 1994;129:170-175. (Pubitemid 24352635)
76. McCune JS, Risler LJ, Phillips BR, et al. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechlorethylation. Drug Metab Dispos. 2005;33:1074-1081. (Pubitemid 41002791)
77. Mohrmann M, Ansorge S, Schonfeld B, et al. Dithiobis- mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells. Pediatr Nephrol. 1994;8:458-465. (Pubitemid 24228640)
78. Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer (letter). Lancet. 2000;355:1075-1076. (Pubitemid 30162815)
79. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460-464. (Pubitemid 37176691)
80. Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: A review. Am J Med Sci. 2007;334:115-124. (Pubitemid 47262919)
81. Daley-Yates PT, McBrien DCH. The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity. Biochem Pharmacol. 1985;34:1423-1428. (Pubitemid 15025777)
82. Daley-Yates PT, McBrien DCH. Enhancement of cisplatin nephrotoxicity by probenecid (letter). Cancer Treat Rep. 1984;68:445-446. (Pubitemid 14125212)
83. Caterson R, Etheredge S, Snitch P, et al. Mechanisms of renal excretion of cisdichlorodiamine platinum. Res Commun Chem Pathol Pharmacol. 1983;41:255-264. (Pubitemid 13043907)
84. Williams PD, Hottendorf GH. Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex. Cancer Treat Rep. 1985;69:875-880. (Pubitemid 15229430)
85. Barros EJG, Boim MA, Santos OFP, et al. Effect of cisplatin on glomerular haemodynamics. Braz J Med Biol Res. 1989;22: 1295-1301.
86. Blochl-Daum B, Pehamberger H, Kurz C, et al. Effects of cisplatin on urinary thromboxane B2 excretion. Clin Pharmacol Ther. 1995;58:418-424.
87. dos Santos OFP, Boim MA, Barros EJG, et al. Effect of platelet-activating factor antagonist BN 52063 on the nephrotoxicity of cisplatin. Lipids. 1991;26:1324-1328.
88. Heidemann HT, Muller S, Mertins L, et al. Effect of aminophylline on cisplatin nephrotoxicity in the rat. Br J Pharmacol. 1989;97:313-318. (Pubitemid 19142732)
89. Singh G. A possible cellular mechanism of cisplatin-induced nephrotoxicity. Toxicology. 1989;58:71-80. (Pubitemid 19233700)
90. Zhang JG, Lindup WE. Cisplatin nephrotoxicity: Decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem Pharmacol. 1994;47:1127-1135.
91. Mundel P, Reiser J. Proteinuria: An enzymatic disease of the podocyte? Kidney Int. 2010;77:571-580.
92. Nielsen R, Christensen EI. Proteinuria and events beyond the slit. Pediatr Nephrol. 2010;25:813-822.